Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449165 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL15871657 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL14841346 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL15871658 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12332956 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL14851356 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL15871655 | 0.96 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL15871879 | 0.94 | CYP2C9 (0.53) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL14851379 | 0.94 | CYP2C9 (0.53) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12423487 | 0.94 | CYP2C9 (0.58) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BLVRB, RRP1B, C1QBP | CYP2C9 2576/4885KCNH2 2848/4885CYP3A4 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.